Amgen drops on less-than-robust 1Q sales
This article was originally published in Scrip
Executive Summary
Amgen traded down 6.2% after the market closed on 23 April and the biotechnology giant announced a 22% jump in first quarter 2013 earnings driven by tax benefits and fewer shares outstanding rather than a robust rise in product sales.